Corbus Pharmaceuticals Holdings, Inc. announced positive topline data from the CANYON-1 Phase 1b clinical trial of CRB-913 for obesity treatment on September 14, 2026. The 16-week, double-blind study enrolled 254 participants and demonstrated statistically significant weight loss at all doses compared to placebo. The 60 mg dose achieved a mean weight loss of 5% at week 12 with no evidence of plateauing. CRB-913 exhibited a favorable safety profile with psychiatric adverse events in line with GLP-1 drugs and lower gastrointestinal side effects than oral incretins. Data will be presented at ObesityWeek 2026, and the company expects to initiate a Phase 2 monotherapy study in the first half of 2027. Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for oncology and obesity.

Corbus Pharmaceuticals Holdings, Inc. reported a net loss of approximately $35.0 million, or $1.81 per share, for the fiscal quarter ended June 30, 2026, compared to a net loss of $17.7 million in the prior year period. Operating expenses increased by $17.0 million to $36.2 million, primarily driven by a $10.0 million development milestone payment for CRB-701 and higher clinical development costs. The company holds $117.9 million in cash, cash equivalents, and investments, which is expected to fund operations into 2028. Corbus obtained FDA clearance to proceed with the registrational TEMPO-1 study of CRB-701 in second-line oropharyngeal cancer, expecting enrollment to begin in September 2026. Additionally, the company concluded the last patient visit for the CANYON-1 Phase 1b study of its obesity drug candidate CRB-913 and anticipates reporting data in September 2026. The firm appointed Leonardo Viana Nicacio as Chief Medical Officer, Nishant Saxena as Chief Business Officer, and Brent Pfeiffenberger to the Board of Directors. Corbus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and obesity.

Corbus Pharmaceuticals Holdings, Inc. entered into a two-year employment agreement with Leonardo Viana Nicacio, MD, effective August 3, 2026, for the position of Chief Medical Officer. The agreement includes an annual base salary of $545,000, a target annual bonus of up to 40% of base salary, and $2,100,000 in equity awards consisting of approximately 75% stock options and 25% restricted stock units. Corbus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases.